TABLE 2

FROM:

Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats

R S Rogers, T M Graziottin, C-S Lin, Y W Kan and T F Lue

Table 2. (Experiment 2) Cavernosometric findings in castrated animals after prevention trial of testosterone replacement (C+testosterone), VEGF protein treatment (C+VEGF), AAV-VEGF gene therapy (C+VEGF gene), or LacZ control (C+LacZ control)

	Flaccid ICP (cm H2O)	ICP after papavarine (cm H2O) *	Maintenance rate (ml/min) **	Drop rate in 1 min (cm H2O)***
C+saline (n=5)	23.4(5.3)	29.4(15)	0.51(0.26)	56.1(15)
C+testosterone (n=7)	28.9(7.5)	87.7(26)	0.09(0.1)	11.7(16)
C+VEGF (n=5)	27.8(5.2)	85.0(28)	0.04(0.09)	9.0(20)
C+VEGF gene (n=11)	23.4(7.1)	61.4(36)	0.04(0.03)	27.8(18)
C+LacZ (n=5)	27.0(6.7)	36.0(12.8)	0.25(0.31)	58.6(8.1)

^*  P0.05, C+saline vs C+testosterone, C+VEGF; C+testosterone vs C+LacZ; C+VEGF vs C+LacZ.

^**  P0.05, C+saline vs C+testosterone, C+VEGF, and C+VEGF gene.

^***  P0.05, C+saline vs C+testosteone, C+VEGF vs C+VEGF gene; C+LacZ vs C+VEGF, C+testosterone, and C+VEGF gene.